In 2022, among drugs launched internationally, markets outside the US accounted for ~35% of total revenues. Between 2010 and 2020, the median global peak revenue of assets launched internationally was $625 million, compared with $152 million for those launched in the US market only. Either as first-time or more seasoned launchers, many biotech companies have gone beyond their home base or are thinking to expand to capture more growth, maximize the impact of their therapies, and help more patients internationally. However, navigating international markets and establishing a strong presence can be a complex endeavor. To unlock success in biotech global expansion, it is critical for companies to select and prioritize countries, design country entry models and strategies, develop launch sequence, and establish cross-functional capabilities. This session will provide a guide on how to approach these critical steps, offering valuable insights on what strategic options are available, what factors to consider, what are some country-specific nuances such as market access and regulatory requirements, what are critical watchout areas, to name a few.